Insulin reduces serum glycosylphosphatidylinositol phospholipase D levels in human type I diabetic patients and streptozotocin diabetic rats.
The enzyme glycosylphosphatidylinositol phospholipase D has a postulated role in the insulin-mimetic signaling pathway of glycosylphosphatidylinositol compounds. We have investigated enzyme activity in the serum of human type I diabetic patients and plasma and tissues of streptozotocin-induced diabetic rats following insulin administration. In the human diabetic patients serum enzyme activity fell by an average of 10.6% (SEM = 2.7; P = 0.008; n = 20) following administration of insulin. In addition serum enzyme activity appeared to be depleted by 27% (SEM = 8.8; P = 0.011; n = 10) compared to nondiabetic controls. In untreated diabetic rats plasma enzyme activity gradually increased 0.3-fold over a 6-week period (P < 0.001; n = 8), this increase was reversed and activity normalized when these animals were treated with insulin. Cloning of the rat glycosylphosphatidylinositol phospholipase D cDNA enabled confirmation of the liver as the principal organ of synthesis. Analysis of mRNA levels in the livers of the diabetic rats showed that gene expression was reduced in the insulin-treated animals compared to the noninsulin-treated controls by 0.7-fold (P = 0.004; n = 4). Tissue enzyme activity was also reduced in the insulin-treated rats; in skeletal muscle enzyme activity was 0.3-fold lower (P = 0.001; n = 4). Insulin therefore decreases glycosylphosphatidylinositol phospholipase D synthesis in diabetic animals resulting in decreased serum enzyme levels, suggesting a relationship between this enzyme and the function of insulin.
Schofield
J N
JN
Department of Immunology and Molecular Pathology, University College, London, United Kingdom. jnschofield@yahoo.com
Stephens
J W
JW
Hurel
S J
SJ
Bell
K M
KM
deSouza
J B
JB
Rademacher
T W
TW
D000818:Animals; D018076:DNA, Complementary / Q000235:genetics / Q000302:isolation & purification; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000201:enzymology*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000201:enzymology*; D015536:Down-Regulation / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D009928:Organ Specificity; D010739:Phospholipase D / Q000097:blood* / Q000235:genetics; D051381:Rats
D018076:DNA, Complementary; D007004:Hypoglycemic Agents; D007328:Insulin; D010739:Phospholipase D; C065017:glycoprotein phospholipase D